A Targeted Proteomic Assay for the Measurement of Plasma Proteoforms Related to Human Aging Phenotypes

Overview

Journal Proteomics

Date 2017 May 17

PMID 28508553

Citations 8

Authors

Richard D Semba

Pingbo Zhang

Min Zhu

Elisa Fabbri

Marta Gonzalez-Freire

Ruin Moaddel

Minghui Geng-Spyropoulos

Luigi Ferrucci

Affiliations

Soon will be listed here.

Abstract

Circulating polypeptides and proteins have been implicated in reversing or accelerating aging phenotypes, including growth/differentiation factor 8 (GDF8), GDF11, eotaxin, and oxytocin. These proteoforms, which are defined as the protein products arising from a single gene due to alternative splicing and PTMs, have been challenging to study. Both GDF8 and GDF11 have known antagonists such as follistatin (FST), and WAP, Kazal, immunoglobulin, Kunitz, and NTR domain-containing proteins 1 and 2 (WFIKKN1, WFIKKN2). We developed a novel multiplexed SRM assay using LC-MS/MS to measure five proteins related to GDF8 and GDF11 signaling, and in addition, eotaxin, and oxytocin. Eighteen peptides consisting of 54 transitions were monitored and validated in pooled human plasma. In 24 adults, the mean (SD) concentrations (ng/mL) were as follows: GDF8 propeptide, 11.0 (2.4); GDF8 mature protein, 25.7 (8.0); GDF11 propeptide, 21.3 (10.9); GDF11 mature protein, 16.5 (12.4); FST, 29.8 (7.1); FST cleavage form FST303, 96.4 (69.2); WFIKKN1, 38.3 (8.3); WFIKKN2, 32.2 (10.5); oxytocin, 1.9 (0.9); and eotaxin, 2.3 (0.5). This novel multiplexed SRM assay should facilitate the study of the relationships of these proteoforms with major aging phenotypes.

Citing Articles

Inaccuracies in plasma oxytocin extraction and enzyme immunoassay techniques.

Gan H, Leeson C, Aitkenhead H, Dattani M Compr Psychoneuroendocrinol. 2023; 15:100188.

PMID: 37360277 PMC: 10285453. DOI: 10.1016/j.cpnec.2023.100188.

Relationships of GDF8 and 11 and Their Antagonists With Decline of Grip Strength Among Older Adults in the Baltimore Longitudinal Study of Aging.

Yamaguchi Y, Zhu M, Moaddel R, Palchamy E, Ferrucci L, Semba R J Gerontol A Biol Sci Med Sci. 2023; 78(10):1793-1798.

PMID: 37235639 PMC: 10562884. DOI: 10.1093/gerona/glad135.

Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.

Ikura H, Endo J, Kitakata H, Moriyama H, Sano M, Fukuda K Int J Mol Sci. 2022; 23(11).

PMID: 35683015 PMC: 9181426. DOI: 10.3390/ijms23116336.

Integrated Multi-Omics for Novel Aging Biomarkers and Antiaging Targets.

Wu L, Xie X, Liang T, Ma J, Yang L, Yang J Biomolecules. 2022; 12(1).

PMID: 35053186 PMC: 8773837. DOI: 10.3390/biom12010039.

Can Blood-Circulating Factors Unveil and Delay Your Biological Aging?.

Rybtsova N, Berezina T, Kagansky A, Rybtsov S Biomedicines. 2020; 8(12).

PMID: 33333870 PMC: 7765271. DOI: 10.3390/biomedicines8120615.

References

Wolfman N, McPherron A, Pappano W, Davies M, Song K, Tomkinson K . Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci U S A. 2003; 100(26):15842-6. PMC: 307655. DOI: 10.1073/pnas.2534946100. View

Bergen 3rd H, Farr J, Vanderboom P, Atkinson E, White T, Singh R . Myostatin as a mediator of sarcopenia versus homeostatic regulator of muscle mass: insights using a new mass spectrometry-based assay. Skelet Muscle. 2015; 5:21. PMC: 4502935. DOI: 10.1186/s13395-015-0047-5. View

Egerman M, Cadena S, Gilbert J, Meyer A, Nelson H, Swalley S . GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration. Cell Metab. 2015; 22(1):164-74. PMC: 4497834. DOI: 10.1016/j.cmet.2015.05.010. View

Sinha M, Jang Y, Oh J, Khong D, Wu E, Manohar R . Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science. 2014; 344(6184):649-52. PMC: 4104429. DOI: 10.1126/science.1251152. View

Ceglarek U, Dittrich J, Becker S, Baumann F, Kortz L, Thiery J . Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC-MS/MS. Proteomics Clin Appl. 2013; 7(11-12):794-801. DOI: 10.1002/prca.201300034. View

Thies R, Chen T, Davies M, Tomkinson K, PEARSON A, Shakey Q . GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding. Growth Factors. 2001; 18(4):251-9. DOI: 10.3109/08977190109029114. View

Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A . Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci U S A. 1988; 85(12):4218-22. PMC: 280398. DOI: 10.1073/pnas.85.12.4218. View

Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi A . Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci. 2011; 66(6):620-6. DOI: 10.1093/gerona/glr025. View

Schafer M, Atkinson E, Vanderboom P, Kotajarvi B, White T, Moore M . Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease. Cell Metab. 2016; 23(6):1207-1215. PMC: 4913514. DOI: 10.1016/j.cmet.2016.05.023. View

10.

Weisman O, Zagoory-Sharon O, Schneiderman I, Gordon I, Feldman R . Plasma oxytocin distributions in a large cohort of women and men and their gender-specific associations with anxiety. Psychoneuroendocrinology. 2012; 38(5):694-701. DOI: 10.1016/j.psyneuen.2012.08.011. View

11.

Ho D, Yeo C, Whitman M . The role and regulation of GDF11 in Smad2 activation during tailbud formation in the Xenopus embryo. Mech Dev. 2010; 127(9-12):485-95. PMC: 4136463. DOI: 10.1016/j.mod.2010.08.004. View

12.

Wintgens K, Dschietzig T, Stoeva S, Paulsson M, Armbruster F . Plasma myostatin measured by a competitive ELISA using a highly specific antiserum. Clin Chim Acta. 2012; 413(15-16):1288-94. DOI: 10.1016/j.cca.2012.04.023. View

13.

Schneyer A, Sidis Y, Gulati A, Sun J, Keutmann H, Krasney P . Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin. Endocrinology. 2008; 149(9):4589-95. PMC: 2553374. DOI: 10.1210/en.2008-0259. View

14.

Brandtzaeg O, Johnsen E, Roberg-Larsen H, Seip K, MacLean E, Gesquiere L . Proteomics tools reveal startlingly high amounts of oxytocin in plasma and serum. Sci Rep. 2016; 6:31693. PMC: 4985690. DOI: 10.1038/srep31693. View

15.

Goldman M, Marlow-OConnor M, Torres I, Carter C . Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr Res. 2007; 98(1-3):247-55. PMC: 2277481. DOI: 10.1016/j.schres.2007.09.019. View

16.

Kondas K, Szlama G, Trexler M, Patthy L . Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11. J Biol Chem. 2008; 283(35):23677-84. PMC: 3259755. DOI: 10.1074/jbc.M803025200. View

17.

Green L, Fein D, Modahl C, Feinstein C, Waterhouse L, Morris M . Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry. 2001; 50(8):609-13. DOI: 10.1016/s0006-3223(01)01139-8. View

18.

Farrah T, Deutsch E, Omenn G, Campbell D, Sun Z, Bletz J . A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol Cell Proteomics. 2011; 10(9):M110.006353. PMC: 3186192. DOI: 10.1074/mcp.M110.006353. View

19.

Panizzutti B, Gubert C, Schuh A, Ferrari P, Bristot G, Fries G . Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: An accelerated aging biomarker?. J Affect Disord. 2015; 182:64-9. DOI: 10.1016/j.jad.2014.12.010. View

20.

Hill J, Qiu Y, Hewick R, Wolfman N . Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol. 2003; 17(6):1144-54. DOI: 10.1210/me.2002-0366. View